Key Takeaway: Tarsus reported strong financial results for the second quarter of 2026, with net product sales of $173.9 million, reflecting a 69% increase year-over-year. The company has raised its full-year sales guidance to between $685 million and $705 million. Additionally, Tarsus is pursuing the acquisition of Alkeus Pharmaceuticals to further develop its retina pipeline, which includes a Phase 3 study.
Market Sentiment Analysis
POSITIVE FACTORS
Generated significant net product sales of $173.9 million.
Achieved a year-over-year sales increase of over 69%.
Increased full-year sales guidance to $685-705 million.
Pending acquisition of Alkeus Pharmaceuticals to enhance pipeline.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+164%
120-day peak, hindsight
Typical move
9%
average across 2 past catalysts
Cash runway
~68 mo
Minimal dilution risk
Lead asset
IRX-101
Phase 3 · Retinal Disease
Full Press Release Details
Generated second quarter 2026 XDEMVY ® net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million Pending acquisition of Alkeus Pharmaceuticals to expand Tarsus’ retina pipeline with a Phase 3
Frequently Asked Questions
What were Tarsus's Q2 2026 net product sales?
Tarsus reported net product sales of $173.9 million for Q2 2026.
How much did Tarsus increase its sales guidance?
Tarsus increased its full-year 2026 sales guidance to $685-705 million.
What acquisition is Tarsus pursuing?
Tarsus is pursuing the acquisition of Alkeus Pharmaceuticals.
What is the focus of Tarsus's pipeline expansion?
The acquisition aims to expand Tarsus's retina pipeline with a Phase 3 study.